Sanofi has launched its cutting-edge Modulus facility in Singapore, marking a pivotal step in advancing global healthcare solutions. Located in Tuas Biomedical Park, this state-of-the-art site features a revolutionary modular design that significantly shortens production timelines and allows rapid adaptation to evolving medical needs.
Representing an investment of approximately 800 million SGD (558 million EUR), Modulus is the first facility of its kind in Asia, complementing its counterpart in France, which will be completed by September 2024.
A New Era in Biopharmaceutical Manufacturing
Designed for sustainable and efficient biopharmaceutical production, Modulus incorporates advanced digital technologies and boasts a low carbon footprint. It can produce up to four vaccines or biologic treatments simultaneously and transition between different production platforms—such as live-attenuated viral vaccines, recombinant protein vaccines, and biotechnology-derived treatments like enzymes and monoclonal antibodies—within days, compared to the weeks or months required in traditional facilities.
The facility’s modular architecture includes 34 interconnected production units, enabling seamless customization of production lines to meet diverse medical demands. This innovation enhances Sanofi’s ability to deliver life-saving treatments rapidly while boosting global pandemic preparedness with scalable and adaptable manufacturing capabilities.
A Vision for Global Health and Sustainability
The launch of Modulus underscores Sanofi’s dedication to innovation, sustainability, and patient care. The facility incorporates green technologies, such as solar panels, green electricity, and recycled materials, aligning with the company’s goal of achieving net-zero carbon emissions by 2045.
By mid-2026, Modulus will create nearly 200 skilled jobs in Singapore, spanning fields like bioprocessing, automation, artificial intelligence, and bioinformatics.
Leadership Perspectives
Beng Chee Yong Poh, Chairman of Singapore’s Economic Development Board, highlighted the strategic importance of the facility:
“Sanofi’s investment strengthens Singapore’s role as a leading center for cutting-edge biopharmaceutical manufacturing. Modulus not only boosts the production of critical therapies but also creates high-value opportunities for Singaporeans while addressing global healthcare needs.”
Brendan O’Callaghan, Executive Vice President of Manufacturing and Supply at Sanofi, emphasized the transformative potential of Modulus:
“This facility reflects Sanofi’s dedication to blending innovation with sustainability, ensuring quicker access to treatments for unmet medical needs while gearing up for future healthcare challenges.”
Liang Hong Koh, Head of Modulus in Singapore, added:
“Modulus is a forward-thinking investment in health and sustainability, contributing to Singapore’s growing biopharmaceutical ecosystem while tackling global health challenges.”
Bridging Science and Transformative Therapies
With its advanced design and unwavering commitment to excellence, Modulus bridges the gap between scientific innovation and the delivery of transformative therapies. It promises faster and more flexible access to critical medicines and vaccines worldwide, setting a new benchmark for the future of healthcare.